Oric Pharmaceuticals, INC Schedule 13G passive stakes

Viking Global Investors LP and associated entities reported a 7.8% beneficial ownership stake in Oric Pharmaceuticals, Inc. as of March 31, 2026.

Venrock Healthcare Capital Partners and affiliates report a 4.2% beneficial ownership stake in ORIC Pharmaceuticals, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Oric Pharmaceuticals, Inc.

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 5.4% in Oric Pharmaceuticals Inc., holding over 5.3 million shares.

Pfizer Inc. has reported a beneficial ownership of 3,442,940 shares, representing 3.3% of the outstanding common stock of ORIC Pharmaceuticals, Inc. as of March 31, 2026.

BlackRock, Inc. has reported a beneficial ownership of 5.6% of ORIC Pharmaceuticals Inc.'s common stock as of December 31, 2025.

The Column Group II and its managing partners have filed an Amendment No. 3 to their Schedule 13G, disclosing a passive beneficial ownership of 3.6% to 3.7% in ORIC Pharmaceuticals, Inc.

Alkeon Capital Management LLC and Panayotis D. Sparaggis have filed an Amendment No. 3 to Schedule 13G, reporting beneficial ownership of 4.6% of Oric Pharmaceuticals, Inc.'s common stock as of September 30, 2025.

Viking Global Investors LP and its affiliates report a 9.99% beneficial ownership stake in Oric Pharmaceuticals, Inc., including common stock and exercisable pre-funded warrants.

Nextech Crossover I SCSp and related entities disclose continued beneficial ownership of 8.4% of ORIC Pharmaceuticals, Inc. common stock.

EcoR1 Capital, LLC and its affiliates have disclosed a 6.9% beneficial ownership stake in ORIC Pharmaceuticals, Inc. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.2% beneficial ownership stake in ORIC PHARMACEUTICALS INC as of June 30, 2025.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly disclosed a 5.1% passive beneficial ownership stake in Oric Pharmaceuticals, Inc., including shares from warrants.

A group of Venrock entities, including Venrock Healthcare Capital Partners III, L.P., has disclosed a 7.7% beneficial ownership stake in ORIC Pharmaceuticals, Inc., primarily through a recent private placement.

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a collective beneficial ownership of 4.5% in ORIC Pharmaceuticals, Inc. as of March 31, 2025.

Viking Global Investors LP and its affiliated entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.2% of Oric Pharmaceuticals, Inc.'s common stock.

Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G, disclosing their passive beneficial ownership in ORIC Pharmaceuticals, Inc. common stock as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a combined beneficial ownership of 3.5% of ORIC Pharmaceuticals Inc.'s common stock as of December 31, 2024.